HLA-DQA1 (Major Histocompatibility Complex, Class II, DQ Alpha 1)

Our findings highlight distinct associations between HLA-DQA1*05 allele subtypes and time to LoR of infliximab and adalimumab in IBD-treated patients. The protective effect of immunomodulator use is allele-specific for adalimumab. These results provide a rationale for incorporating HLA testing into personalized anti-TNF management to optimize treatment durability.

In Taiwanese IBD patients, HLA-C*03:04:01 and HLA-B*15:18:01 were significantly associated with ADA development to infliximab and adalimumab, respectively. HLA-DQA1*05 was not predictive, highlighting ethnic differences in genetic predisposition to immunogenicity.

Our findings demonstrate the feasibility of combining spatial transcriptomics with AI-driven histopathological analysis for biomarker validation. This integrative framework provides a foundation for future population-scale studies leveraging spatial omics to evaluate arsenic-associated gene signatures and assess their relevance in bladder cancer risk stratification and disease progression.

In addition, a high-risk signature score was linked to low infiltrating levels of most immune cells and a high tumor purity in the tumor microenvironment, as well as low IC50 values to several common chemotherapeutics, such as docetaxel, gefitinib, and erlotinib. Among the five prognostic genes, HLA-DQA1 harbored a relatively higher alteration frequency in LUAD (3%, alteration type: amplification). The five platelet-derived prognostic genes might be potential targets or biomarkers in lung cancer.

The HLA risk profile typical of sub-Saharan African population was observed in Ethiopians with T1D. Furthermore, they have a notably high prevalence of autoantibodies associated with T1D, CD, and AITD, which differs from earlier reports from the region but aligns with patterns observed in Caucasians.

The developed PRS showed robust predictive ability for PCa in the Taiwanese population and may inform future risk stratification and personalized interventions.

P1, N=56, Active, not recruiting, Chugai Pharmaceutical Co., Ltd | Recruiting --> Active, not recruiting

We conducted a single-center cohort analysis of patients with Crohn's disease (CD) and Ulcerative colitis (UC) who initiated treatment with infliximab or adalimumab between January 2020 and March 2023. Optimizing anti-TNF induction with a dashboard-guide dosing strategy proves to be a valuable approach to enhance treatment durability and clinical outcomes in inflammatory bowel disease patients. Immunogenicity appears to be mitigated by the model, which even mitigates the impact of immunomodulators and overcomes HLA DQA1*05 effect.

Integrating next-generation sequencing data of HLA genes in genomic and epigenomic data can offer a comprehensive understanding of the molecular mechanisms underlying HBV infection. This integrated approach will help identify new biomarkers, deeply understand the complex interactions between genetic and epigenetic factors, and facilitate the development of personalized prevention and treatment strategies.

A single-center, prospective study was conducted on patients with IBD who were naïve to biological treatment and were initiating therapy with anti-TNF agents, vedolizumab, or ustekinumab. Can we rely on HLA to predict resistance to biological therapy in patients with IBD?URL: https://clinicaltrials.gov/study/NCT05040854?cond=Can%20we%20rely%20on%20HLA&rank=1. Registration number: NCT05040854 (clinicaltrials.gov).

TYMS was a hub gene in the prognostic signature, and was strongly associated with LUAD progression and cell proliferation in the experimental validation. The lung TRM cell-related prognostic signature is an effective tool for predicting the prognosis and therapeutic outcomes of patients with LUAD.

Tertiary lymphoid structures (TLSs) serve as a promising prognostic biomarker in hepatoblastoma (HB). Our study demonstrates that TLS-positive patients exhibit significantly prolonged overall survival. TLSs contribute to the tumor immune microenvironment by recruiting cytotoxic immune cells. These findings provide new insights into TLSs as a potential immunotherapeutic target for HB patients.